Novo shares lost nearly a fifth of their value after an experimental combination treatment called cagrisema fell short of the ...

The clearance of Tryngolza gives Ionis its first wholly-owned, marketed medicine. Elsewhere, Robert Temple became the latest ...

An startup formed by KdT Ventures intends to test the drug, which was once licensed to Merck and evaluated in multiple ...

Mixed results from a study focused on lower back pain left analysts wanting as well as confused about Vertex's plans to forge ...

The company is planning a “broad Phase 3 program” for two anticoagulants after they outperformed marketed medicines in a pair ...

Pain has really been out of favor in the industry up until very recently,” said John Mulcahy, SiteOne Therapeutics’ CEO. The ...

Led by former Seagen CEO David Epstein, the startup claims it has a drug that could stand out from other PD1- and ...

The company is scrapping two drugs aimed at targets called TIGIT and LAG-3, both of which were in the middle of Phase 3 ...

While the pharma is still developing a MorphoSys drug acquired in its $2.9 billion deal for the biotech, it is closing down sites in the U.S. and Germany.

News of Merck’s licensing of Hansoh’s preclinical medicine pressured shares in Viking and other obesity drug developers seen ...

Bumpus replaced agency veteran Janet Woodcock as principal deputy commissioner in February 2024. She was previously the FDA’s ...

Bruce Cozadd, who co-founded the company two decades ago, will step down once a successor is found. Jazz aims to complete its ...